ライフサイエンスコーパス: bone marrow biopsy

1 sponse to up to 31 drugs within 5 days after bone marrow biopsy.

2 red with tryptase in estimating the need for bone marrow biopsy.

3 cell aggregates, and atypical mast cells on bone marrow biopsy.

4 ish M2, t[8;21][q22;q22.1]) was diagnosed on bone marrow biopsy.

5 fficient accuracy to replace routine staging bone marrow biopsy.

6 , urine and serum immunoelectrophoresis, and bone marrow biopsy.

7 the diagnosis usually depends on results of bone marrow biopsy.

8 emic mastocytosis) and thus candidates for a bone marrow biopsy.

9 ng pure red cell aplasia (PRCA) confirmed by bone marrow biopsy.

10 pared with hematologic response criteria and bone marrow biopsies.

11 ot spot density compared with normal control bone marrow biopsies.

12 nical relevance of expression in 55 archival bone marrow biopsies.

13 e myeloid leukemia (AML) routinely undergo a bone marrow biopsy 7-10 days after induction chemotherap

14 Analysis of bone marrow biopsies after CTL019 revealed 8 patients wi

15 Response was assessed by weekly CBC and bone marrow biopsy after cycle 2 and after each subseque

16 Bone marrow biopsy analysis showed 5% plasma cells, whic

17 Bone marrow biopsies and imaging were performed by cycle

18 nohistochemically by factor VIII staining of bone marrow biopsies and quantified by assessment of mic

19 umbers of blood vessels were measured in 145 bone marrow biopsies and the levels of vascular endothel

20 Patients with low-risk MGUS can safely defer bone marrow biopsy and advanced imaging, and should unde

21 The patient's bone marrow biopsy and aspirate displayed unique patholo

22 enia and negligible gene marking, diagnostic bone marrow biopsy and aspirate were performed at day 88

23 A bone marrow biopsy and aspiration revealed a mildly hype

24 tiple myeloma was diagnosed and confirmed by bone marrow biopsy and aspiration.

25 ermediate- and high-risk MGUS should trigger bone marrow biopsy and bone imaging to detect overt MM a

26 Congo red stain on bone marrow biopsy and fat pad aspirate was negative for

27 cible ischemia in Tc-99m SPECT who underwent bone marrow biopsy and were allocated to cells (n=16) or

28 cible ischemia in Tc-99m SPECT who underwent bone marrow biopsy and were allocated to cells (n=16) or

29 work-up consisted of a complete blood count, bone marrow biopsy, and immunohistochemical and histoche

30 agnosis, in the selection of those needing a bone marrow biopsy, and in the documentation of disease

31 ria to identify those patients who require a bone marrow biopsy, and whether the pathogenesis of IA i

32 s or suspicious lymphocytic infiltrates in a bone marrow biopsy as the sole suggestion of residual di

33 )At-radioimmunotherapy, after lymph node and bone marrow biopsies at 2-4 and/or 19 h after injection.

34 notyping, as well as follow-up allograft and bone marrow biopsies at 3 and 9 months, including analys

35 The diagnosis of 661 PMF patients with a bone marrow biopsy at presentation was revised according

36 one-metastatic CRPC who underwent transiliac bone marrow biopsy between October 2007 and March 2010.

37 Bone marrow biopsies (BMB) are performed before/after th

38 B-cell lymphoma (DLBCL), the sensitivity of bone marrow biopsy (BMB) for the detection of bone marro

39 Skin and bone marrow biopsies can thus be used to generate de nov

40 aled an IgG kappa monoclonal gammopathy, and bone marrow biopsy confirmed smoldering multiple myeloma

41 A percutaneous biopsy of the mass and bone marrow biopsy confirmed the diagnosis of primary ad

42 Serum paraproteins and/or light chains or bone marrow biopsy defined response.

43 araspinal mass was discovered, and tumor and bone marrow biopsies disclosed rhabdomyosarcoma.

44 l and transformed plasma cells from the same bone marrow biopsy enables discovery of patient-specific

45 agrelide therapy should undergo surveillance bone marrow biopsy every 2 to 3 years and that those who

46 Bone marrow biopsy exhibited mostly mixed patterns of sm

47 r urticaria pigmentosa or the characteristic bone marrow biopsy finding of multifocal mast-cell aggre

48 with MCAS-T underwent evaluation, including bone marrow biopsy, for a MC disorder.

49 iogenesis in plasmacytoma biopsy samples and bone marrow biopsies from 25 patients.

50 rt a comprehensive proteogenomic analysis of bone marrow biopsies from 252 uniformly treated AML pati

51 We evaluated bone marrow biopsies from 40 children with newly diagnos

52 iption factor (MITF), is highly expressed in bone marrow biopsies from 9 of 10 patients with systemic

53 Immunohistochemical staining of bone marrow biopsies from most of these patients reveale

54 Evaluation of bone marrow biopsies from myeloma patients revealed a st

55 Moreover, analysis of bone marrow biopsies from myeloma patients reveals a pos

56 In bone marrow biopsies from patients with DBA or del(5q) m

57 Bone marrow biopsies from patients with multiple myeloma

58 Bone marrow biopsies from patients with systemic mastocy

59 simultaneous analysis of WM patient sera and bone marrow biopsies identified a set of dysregulated cy

60 nohistochemical paraffin section staining of bone marrow biopsies in the staging of B-cell malignant

61 Although bone marrow biopsies in these patients showed increased

62 t optimal test indicating the necessity of a bone marrow biopsy in ISM-suspected patients.

63 commonly used test to estimate the need for bone marrow biopsy in patients suspected to have indolen

64 Bone marrow biopsy in patients with prolonged or late cy

65 tumor DNA (ctDNA) is directly comparable to bone marrow biopsy in representing the genomic heterogen

66 o detected by immunohistochemistry in normal bone marrow biopsies, indicating an in vivo function.

67 oring response to therapy; also, the role of bone marrow biopsy is being revisited.

68 A bone marrow biopsy is no longer indicated for the routin

69 ause of variable symptoms until confirmatory bone marrow biopsy is performed.

70 Bone marrow biopsies largely replaced by PCa were analyz

71 Bone marrow biopsy may reveal hemophagocytosis and marro

72 In-DOTA-anti-CD45 antibody (BC8) imaging and bone marrow biopsy measurements to ascertain the biodist

73 aranase activity in the plasma isolated from bone marrow biopsies of 100 patients reveals 86 positive

74 e to quantify IDO-1 expression on diagnostic bone marrow biopsies of AML patients in order to facilit

75 this cutoff correctly classifies diagnostic bone marrow biopsies of MPN,U patients specified upon fo

76 In this investigation, bone marrow biopsies of the anterior iliac crest were ex

77 Responses were assessed by bone marrow biopsy on day 15 of the first course and by

78 ic health record; review of laboratory data; bone marrow biopsy pathology analysis; and in vitro enzy

79 drome features with the exception that their bone marrow biopsy pathology revealed abundant neutrophi

80 decreased risk of identifying pathology on a bone marrow biopsy performed for a low WBC count (odds-r

81 Bone marrow biopsy performed in two of these five patien

82 e and post-treatment assessments were serial bone-marrow biopsy, peripheral blood collections, stagin

83 g/gm Cr corresponded with the high degree of bone marrow biopsies positive for atypical mast cells, t

84 re staged using clinical assessment, CT, and bone marrow biopsy (RATHL stage).

85 Bone marrow biopsy revealed hypercellular marrow.

86 Bone marrow biopsy revealed no evidence of infectious or

87 MAC loads in bilateral bone marrow biopsy samples from 7 subjects were highly c

88 a murine model of Ph+ B-ALL as well as human bone marrow biopsy samples to assess the fundamental nat

89 90 ng/mL, <15% infiltration by mast cells in bone marrow biopsy-sections, and diagnosis of ISM were i

90 Serial bone marrow biopsies showed normalization of trilineage

91 Comparison with bone marrow biopsies showed that FDG-PET was not reliabl

92 Bone marrow biopsy showed 60% infiltration with lambda l

93 Immunohistochemistry of bone marrow biopsy showed an increased number of plasma

94 Complete clinical staging and bone marrow biopsy showed no signs of disseminated disea

95 After histologic analysis of the bone marrow biopsy specimen, diagnosis of Waldenstrom ma

96 In this study, bone marrow biopsy specimens from 36 patients with T-cel

97 The TMA was constructed using pretreatment bone marrow biopsy specimens from 64 adult patients with

98 orulae were detected on peripheral smear and bone marrow biopsy specimens, and PCR amplified Ehrlichi

99 rum lgs, and immunohistochemical staining of bone marrow biopsy specimens.

100 Analysis of bone marrow-biopsy specimens obtained from two patients

101 Immunohistochemical analysis of bone marrow-biopsy specimens showed that only myeloma ce

102 These data suggest that bone marrow biopsy using antigen-targeted magnetic nanop

103 Bone marrow biopsy was done on day -7 to estimate radiat

104 s was nondiagnostic, and lumbar puncture and bone marrow biopsies were negative.

105 Bone marrow biopsies were obtained 14-24 h after infusio

106 One hundred eighty-four bone marrow biopsies were obtained, and 48 had prostate

107 Between 1989 and 1994, bone marrow biopsies were performed on 393 breast cancer

108 ent monoclone of IgG1, the patient underwent bone marrow biopsy which revealed Monoclonal Gammopathy

109 PDGFR-expressing tumor declined on serial bone marrow biopsies with combination therapy alone.